Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has already been approved in the US, China, Japan, and other world markets for people with the early signs of Alzheimer's.

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say it shouldn't be approved.

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease med Kisunla (donanemab) also got a rejection from EU regulators. | After failing to pass muster with England’s drug reimbursement watchdog earlier this month,